Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

beclobrinic acid

Known as: 2-(4 ((4-chlorophenyl)methyl)phenoxy)-2-methyl butanoic acid, beclobric acid 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Clofibrate
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Effects of clofibric and beclobric acid in rat and monkey hepatocyte primary culture: influence on peroxisomal and mitochondrial β-oxidation and the activity of catalase, glutathione S-transferase…
The effect of hypolipidaemic compounds on peroxisomal fatty acid β-oxidation and on peroxisome morphology in the liver differs… Expand
  • figure I
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1993
1993
In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers.
Acyl glucuronides are known to be labile conjugates, which undergo hydrolysis and bind irreversibly to proteins. The lipid… Expand
Is this relevant?
1993
1993
Pharmacokinetics of beclobric acid enantiomers and their conjugates after single and multiple oral dosage of racemic beclobrate.
The chiral lipid regulating agent beclobrate (CAS 55937-99-0), which was marketed as racemate, is - like clofibrate - rapidly… Expand
Is this relevant?
1991
1991
Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA).
The major biotransformation pathway for the chiral lipid-regulating agent beclobrate is conversion to the corresponding… Expand
Is this relevant?
1990
1990
The effect of beclobric acid and clofibric acid on peroxisomal beta-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes.
The peroxisome-proliferating effects of clofibric acid and beclobric acid were studied in primary cultures of hepatocytes derived… Expand
Is this relevant?
1990
1990
Effective hypolipidaemic therapy with beclobrate in haemodialysis patients: interference with L-carnitine.
The lipid-reducing effects of a new fibric acid derivative (beclobrate, 100 mg/day), L-carnitine (15 mg/ kg b.w. thrice weekly i… Expand
Is this relevant?
1987
1987
Induction of peroxisomal fatty acyl-CoA oxidase and microsomal laurate hydroxylase activities by beclobric acid and two metabolites in primary cultures of rat hepatocytes.
Beclobrate [2-(4-[(4-chlorophenyl)methyl]phenoxy)-2-methylbutyric acid ethyl ester], a structural analog of clofibrate, is used… Expand
Is this relevant?
1987
1987
[Pharmacokinetics and bioequivalence of two peroral beclobrate preparations].
The pharmacokinetics of beclobrate (ethyl(+/-)-2-[[alpha-(p-chlorophenyl)-p-tolyl]-oxy]-2-methylbutyrate, SGD 24774), a new lipid… Expand
Is this relevant?
1985
1985
Beclobrinic acid--a new hypolipidemic agent--inhibits in vitro human platelet activation by blocking prostaglandin synthesis.
Effects and the mechanism of the antiplatelet actions of beclobrinic acid, free acid form of a new hypolipidemic agent beclobrate… Expand
Is this relevant?
1985
1985
[Metabolism of beclobrate in rat and man].
The major pathway of biotransformation of beclobrate [(2-[4-[(4-chlorophenyl)methyl]phenoxy]-2-methylbutyric acid ethyl ester] is… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE